The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Joshua M. Fine, insider at Cyclo Therapeutics

Joshua M. Fine Insider Information

Mr. Fine was appointed our Chief Financial officer in June 2019 and brings more than 15 years of operational, investment banking and investing experience in Pharmaceutical and Biotechnology sectors.  Josh brings to Cyclo financial expertise and an in-depth understanding of public company accounting.

Mr. Fine also brings significant experience in mergers and acquisitions, business development and strategy development.  Josh served as Senior Vice President of Finance and Operations at Icagen, where as part of the management team he worked on two transformational acquisitions.  After acquiring assets and talent out of Sanofi and Pfizer, Josh worked to transition both operating teams into financial and operational alignment.  While at Icagen, Josh worked closely with the CEO to successfully negotiate and sign multiple licensing deals with Roche, Sanofi, and the Cystic Fibrosis Foundation.  Additionally, Josh was part of the team that led to the strategic sale of Icagen to Ligand in April of 2020.

Prior to joining Icagen Mr. Fine was an investment banking professional focused in the Life Science and Healthcare sectors.  In this role Josh was a part of or led, financings, strategic partnerships, mergers and acquisitions and advisory work.

What is Joshua M. Fine's net worth?

The estimated net worth of Joshua M. Fine is at least $34,138.00 as of March 29th, 2021. Mr. Fine owns 16,900 shares of Cyclo Therapeutics stock worth more than $34,138 as of July 3rd. This net worth evaluation does not reflect any other assets that Mr. Fine may own. Learn More about Joshua M. Fine's net worth.

How old is Joshua M. Fine?

Mr. Fine is currently 40 years old. There are 5 older executives and no younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics is Mr. George L. Fails, Exec. VP and Operations Mang., who is 77 years old. Learn More on Joshua M. Fine's age.

How do I contact Joshua M. Fine?

The corporate mailing address for Mr. Fine and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected] Learn More on Joshua M. Fine's contact information.

Has Joshua M. Fine been buying or selling shares of Cyclo Therapeutics?

Joshua M. Fine has not been actively trading shares of Cyclo Therapeutics during the past quarter. As an example of a recent trade by , 0 shares of the business's stock in a transaction that occurred on Sunday, July 3rd. Learn More on Joshua M. Fine's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 18 times. They purchased a total of 75,754 shares worth more than $307,526.22. The most recent insider tranaction occured on May, 20th when Director Francis Patrick Ostronic bought 5,000 shares worth more than $10,200.00. Insiders at Cyclo Therapeutics own 12.3 % of the company. Learn More about insider trades at Cyclo Therapeutics.

Information on this page was last updated on 5/20/2022.

Joshua M. Fine Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2021Buy50$7.40$370.0016,900View SEC Filing Icon  
See Full Table

Joshua M. Fine Buying and Selling Activity at Cyclo Therapeutics

This chart shows Joshua M Fine's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Read More

Today's Range

Now: $2.02
Low: $1.93
High: $2.10

50 Day Range

MA: $2.24
Low: $1.97
High: $3.00

2 Week Range

Now: $2.02
Low: $1.88
High: $10.18

Volume

8,108 shs

Average Volume

17,530 shs

Market Capitalization

$17.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!